BMT for severe aplastic anemia using cyclosporine

W. Stratford May, L. L. Sensenbrenner, W. H. Burns, R. Ambinder, M. P. Carroll, C. A. Griffin, R. J. Jones, C. B. Miller, E. D. Mellits, G. B. Vogelsang, J. E. Wagner, J. R. Wingard, Andrew M Yeager, G. W. Santos

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Between 1984 and 1991 24 patients with severe aplastic anemia (SAA) were transplanted with HLA identical sibling donor BM. The overall long-term survival was 79 ± 8%. The average age was 21 years (range 4-53 years) and the median pre-transplant disease duration was 35 days (range 12-2998 days). Over one-half (15 of 24) of the patients had received > 10 units of blood product transfusions prior to BMT. The pre-transplant conditioning regimen consisted of 200 mg/kg cyclophosphamide (CY). Cyclosporine (CYA) was administered from 2 days prior to BMT and continued for 6-12 months. Two of the 24 patients failed to achieve primary engraftment (FTE). One of these patients had autologous recovery of BM function and is alive and well. Five of the 22 patients who engrafted failed to sustain engraftment (FTSE). Of these, three are alive and well following a second BMT or marrow boost. Only 1 of the 22 patients who engrafted had clinically significant (i.e. Stage II-IV) acute GVHD. No patient developed chronic GVHD. Our results indicate that BMT following a regimen consisting of CY with the continuous use of CYA in the post-transplant period is well tolerated and associated with excellent long-term survival. The high incidence of secondary graft instability (i.e. FTSE), however, suggests that future studies should focus on post-transplanation immunomodulation.

Original languageEnglish (US)
Pages (from-to)459-464
Number of pages6
JournalBone Marrow Transplantation
Volume11
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Aplastic Anemia
Cyclosporine
Transplants
Cyclophosphamide
Survival
Immunomodulation
Recovery of Function
Blood Transfusion
Siblings
Bone Marrow
Tissue Donors
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Stratford May, W., Sensenbrenner, L. L., Burns, W. H., Ambinder, R., Carroll, M. P., Griffin, C. A., ... Santos, G. W. (1993). BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplantation, 11(6), 459-464.

BMT for severe aplastic anemia using cyclosporine. / Stratford May, W.; Sensenbrenner, L. L.; Burns, W. H.; Ambinder, R.; Carroll, M. P.; Griffin, C. A.; Jones, R. J.; Miller, C. B.; Mellits, E. D.; Vogelsang, G. B.; Wagner, J. E.; Wingard, J. R.; Yeager, Andrew M; Santos, G. W.

In: Bone Marrow Transplantation, Vol. 11, No. 6, 1993, p. 459-464.

Research output: Contribution to journalArticle

Stratford May, W, Sensenbrenner, LL, Burns, WH, Ambinder, R, Carroll, MP, Griffin, CA, Jones, RJ, Miller, CB, Mellits, ED, Vogelsang, GB, Wagner, JE, Wingard, JR, Yeager, AM & Santos, GW 1993, 'BMT for severe aplastic anemia using cyclosporine', Bone Marrow Transplantation, vol. 11, no. 6, pp. 459-464.
Stratford May W, Sensenbrenner LL, Burns WH, Ambinder R, Carroll MP, Griffin CA et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplantation. 1993;11(6):459-464.
Stratford May, W. ; Sensenbrenner, L. L. ; Burns, W. H. ; Ambinder, R. ; Carroll, M. P. ; Griffin, C. A. ; Jones, R. J. ; Miller, C. B. ; Mellits, E. D. ; Vogelsang, G. B. ; Wagner, J. E. ; Wingard, J. R. ; Yeager, Andrew M ; Santos, G. W. / BMT for severe aplastic anemia using cyclosporine. In: Bone Marrow Transplantation. 1993 ; Vol. 11, No. 6. pp. 459-464.
@article{acd65fdcf01948a2a4336f56c5b978ac,
title = "BMT for severe aplastic anemia using cyclosporine",
abstract = "Between 1984 and 1991 24 patients with severe aplastic anemia (SAA) were transplanted with HLA identical sibling donor BM. The overall long-term survival was 79 ± 8{\%}. The average age was 21 years (range 4-53 years) and the median pre-transplant disease duration was 35 days (range 12-2998 days). Over one-half (15 of 24) of the patients had received > 10 units of blood product transfusions prior to BMT. The pre-transplant conditioning regimen consisted of 200 mg/kg cyclophosphamide (CY). Cyclosporine (CYA) was administered from 2 days prior to BMT and continued for 6-12 months. Two of the 24 patients failed to achieve primary engraftment (FTE). One of these patients had autologous recovery of BM function and is alive and well. Five of the 22 patients who engrafted failed to sustain engraftment (FTSE). Of these, three are alive and well following a second BMT or marrow boost. Only 1 of the 22 patients who engrafted had clinically significant (i.e. Stage II-IV) acute GVHD. No patient developed chronic GVHD. Our results indicate that BMT following a regimen consisting of CY with the continuous use of CYA in the post-transplant period is well tolerated and associated with excellent long-term survival. The high incidence of secondary graft instability (i.e. FTSE), however, suggests that future studies should focus on post-transplanation immunomodulation.",
author = "{Stratford May}, W. and Sensenbrenner, {L. L.} and Burns, {W. H.} and R. Ambinder and Carroll, {M. P.} and Griffin, {C. A.} and Jones, {R. J.} and Miller, {C. B.} and Mellits, {E. D.} and Vogelsang, {G. B.} and Wagner, {J. E.} and Wingard, {J. R.} and Yeager, {Andrew M} and Santos, {G. W.}",
year = "1993",
language = "English (US)",
volume = "11",
pages = "459--464",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - BMT for severe aplastic anemia using cyclosporine

AU - Stratford May, W.

AU - Sensenbrenner, L. L.

AU - Burns, W. H.

AU - Ambinder, R.

AU - Carroll, M. P.

AU - Griffin, C. A.

AU - Jones, R. J.

AU - Miller, C. B.

AU - Mellits, E. D.

AU - Vogelsang, G. B.

AU - Wagner, J. E.

AU - Wingard, J. R.

AU - Yeager, Andrew M

AU - Santos, G. W.

PY - 1993

Y1 - 1993

N2 - Between 1984 and 1991 24 patients with severe aplastic anemia (SAA) were transplanted with HLA identical sibling donor BM. The overall long-term survival was 79 ± 8%. The average age was 21 years (range 4-53 years) and the median pre-transplant disease duration was 35 days (range 12-2998 days). Over one-half (15 of 24) of the patients had received > 10 units of blood product transfusions prior to BMT. The pre-transplant conditioning regimen consisted of 200 mg/kg cyclophosphamide (CY). Cyclosporine (CYA) was administered from 2 days prior to BMT and continued for 6-12 months. Two of the 24 patients failed to achieve primary engraftment (FTE). One of these patients had autologous recovery of BM function and is alive and well. Five of the 22 patients who engrafted failed to sustain engraftment (FTSE). Of these, three are alive and well following a second BMT or marrow boost. Only 1 of the 22 patients who engrafted had clinically significant (i.e. Stage II-IV) acute GVHD. No patient developed chronic GVHD. Our results indicate that BMT following a regimen consisting of CY with the continuous use of CYA in the post-transplant period is well tolerated and associated with excellent long-term survival. The high incidence of secondary graft instability (i.e. FTSE), however, suggests that future studies should focus on post-transplanation immunomodulation.

AB - Between 1984 and 1991 24 patients with severe aplastic anemia (SAA) were transplanted with HLA identical sibling donor BM. The overall long-term survival was 79 ± 8%. The average age was 21 years (range 4-53 years) and the median pre-transplant disease duration was 35 days (range 12-2998 days). Over one-half (15 of 24) of the patients had received > 10 units of blood product transfusions prior to BMT. The pre-transplant conditioning regimen consisted of 200 mg/kg cyclophosphamide (CY). Cyclosporine (CYA) was administered from 2 days prior to BMT and continued for 6-12 months. Two of the 24 patients failed to achieve primary engraftment (FTE). One of these patients had autologous recovery of BM function and is alive and well. Five of the 22 patients who engrafted failed to sustain engraftment (FTSE). Of these, three are alive and well following a second BMT or marrow boost. Only 1 of the 22 patients who engrafted had clinically significant (i.e. Stage II-IV) acute GVHD. No patient developed chronic GVHD. Our results indicate that BMT following a regimen consisting of CY with the continuous use of CYA in the post-transplant period is well tolerated and associated with excellent long-term survival. The high incidence of secondary graft instability (i.e. FTSE), however, suggests that future studies should focus on post-transplanation immunomodulation.

UR - http://www.scopus.com/inward/record.url?scp=0027225748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027225748&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 459

EP - 464

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -